title: Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.
abstract: Patients with high-risk neuroblastoma have a poor prognosis, especially in cases of recurrent or relapsed disease. Iodine-131-labeled meta-iodobenzylguanidine ((131)I-MIBG) can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. Establishing an MIBG therapy program requires a great deal of planning, availability of hospital resources, and the commitment of individuals with training and expertise in multiple disciplines. Providing (131)I-MIBG therapy requires physical facilities and procedures that permit patient care in compliance with the standards for occupational and community exposure to radiation. Establishment of a successful (131)I-MIBG therapy program also requires a detailed operational plan and appropriate education for caregivers, parents, and patients.
authors.affiliation: Department of Pediatric Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Shusterman
authors.forename: Frederick D
authors.initials: FD
authors.lastname: Grant
authors.forename: William
authors.initials: W
authors.lastname: Lorenzen
authors.forename: Royal T
authors.initials: RT
authors.lastname: Davis
authors.forename: Stephen
authors.initials: S
authors.lastname: Laffin
authors.forename: Laura A
authors.initials: LA
authors.lastname: Drubach
authors.forename: Frederic H
authors.initials: FH
authors.lastname: Fahey
authors.forename: S Ted
authors.initials: ST
authors.lastname: Treves
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D004493:Education; D006801:Humans; D009447:Neuroblastoma / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*
chemical_list: D019797:3-Iodobenzylguanidine